Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
暂无分享,去创建一个
Andrea Cipriani | Georgia Salanti | Corrado Barbui | Sarah Stockton | Loukia M Spineli | John R Geddes | G. Goodwin | J. Rendell | J. Geddes | A. Cipriani | C. Barbui | G. Salanti | S. Stockton | M. Purgato | L. Spineli | Guy M Goodwin | Jennifer Rendell | Rachel Brown | Marianna Purgato | Rachel Brown
[1] J. Geddes,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.
[2] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[3] John M. Davis,et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis , 2010, Schizophrenia Research.
[4] M. Sculpher,et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis , 2012, PharmacoEconomics (Auckland).
[5] R. Baldessarini,et al. Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials , 2011, Neuropsychopharmacology.
[6] Georgia Salanti,et al. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.
[7] J. Cairns,et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. , 2007, Health technology assessment.
[8] S Dias,et al. Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.
[9] Julian P T Higgins,et al. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. , 2009, Journal of clinical epidemiology.
[10] G. Dunn,et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. , 2007, Health technology assessment.
[11] R. C. Young,et al. A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.
[12] M. DelBello,et al. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. , 2010, Bipolar disorders.
[13] M. Tohen,et al. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. , 2010, The international journal of neuropsychopharmacology.
[14] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[15] Arun Ravindran,et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. , 2013, Bipolar disorders.
[16] M. Alda,et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. , 2013, Bipolar disorders.
[17] Georgia Salanti,et al. Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.
[18] H. Möller,et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[19] G. Goodwin. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. , 2009, Journal of psychopharmacology.
[20] John M. Davis,et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.
[21] G. Salum,et al. Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) , 2018, International journal of methods in psychiatric research.
[22] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[23] R. Licht. Limitations in randomised controlled trials evaluating drug effects in mania , 2001, European archives of psychiatry and clinical neuroscience.
[24] Alan D. Lopez,et al. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.
[25] L. Hranov,et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.
[26] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[27] S. Leucht,et al. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. , 2007, Archives of general psychiatry.
[28] R. Kahn,et al. Eff ectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder : an open randomised clinical trial , 2008 .
[29] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[30] P. Buckley. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial , 2013 .
[31] D. Altman,et al. Chapter 8: Assessing risk of bias in included studies , 2008 .